Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/51109
Title: INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study
Authors: de Andrade, Gabriel Costa [UNIFESP]
de Oliveira Dias, Joao Rafael [UNIFESP]
Maia, Andre [UNIFESP]
Farah, Michel Eid [UNIFESP]
Meyer, Carsten H. [UNIFESP]
Rodrigues, Eduardo Buchele [UNIFESP]
Keywords: diabetic retinopathy
diabetic macular edema (DME)
anti-VEGF
ziv-aflibercept
Issue Date: 2016
Publisher: Lippincott Williams & Wilkins
Citation: Retina-The Journal Of Retinal And Vitreous Diseases. Philadelphia, v. 36, n. 9, p. 1640-1645, 2016.
Abstract: Purpose:Diabetic macular edema is the leading cause of blindness in young adults in developed countries. Beyond metabolic control, several therapies have been studied such as laser treatment and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor drugs. In terms of public health the long-term treatment with the current available drugs is very expensive and new therapies with the same or better effect should be investigated. This study sought to evaluate the efficacy and safety of intravitreal injections of ziv-aflibercept for the treatment of diabetic macular edema.Methods:Seven consecutive patients with diabetic macular edema were enrolled. A complete examination, including full-field electroretinography, visual acuity, central retinal thickness, and evaluation of systemic and ocular complications, was performed before and at 24 weeks after intravitreal injections of ziv-aflibercept. The seven patients were submitted to six consecutive intravitreal injections of ziv-aflibercept with a 4-week interval.Results:No significant differences were found in the amplitude or implicit time of any electroretinography component after intravitreal injections of ziv-aflibercept, and no systemic or ocular complication was observed. The improvement of visual acuity was significant at 24 weeks (P < 0.05). The central retinal thickness significantly decreased during the course of 24 weeks.Conclusion:Intravitreal injections of ziv-aflibercept seem to be a safe and effective treatment option for diabetic macular edema.
URI: http://repositorio.unifesp.br/handle/11600/51109
ISSN: 0275-004X
Other Identifiers: http://dx.doi.org/10.1097/IAE.0000000000001000
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.